TY - JOUR
T1 - Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
AU - Kurup, Drishya
AU - Malherbe, Delphine C.
AU - Wirblich, Christoph
AU - Lambert, Rachael
AU - Ronk, Adam J.
AU - Diba, Leila Zabihi
AU - Bukreyev, Alexander
AU - Schnell, Matthias J.
N1 - Funding Information:
This project was financed in part by a grant from the Commonwealth of Pennsylvania, Department of Community and Economic Development” and a grant from Bharat Biotech, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
Copyright: © 2021 Kurup et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/3
Y1 - 2021/3
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
UR - http://www.scopus.com/inward/record.url?scp=85104047883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104047883&partnerID=8YFLogxK
U2 - 10.1371/JOURNAL.PPAT.1009383
DO - 10.1371/JOURNAL.PPAT.1009383
M3 - Article
C2 - 33765062
AN - SCOPUS:85104047883
SN - 1553-7366
VL - 17
JO - PLoS pathogens
JF - PLoS pathogens
IS - 3
M1 - e1009383
ER -